المؤلفون: A. M. Suleymanova, D. Yu. Kachanov, E. N. Imyanitov, V. Yu. Roshchin, T. V. Shamanskaya, S. R. Varfolomeeva, А. М. Сулейманова, Д. Ю. Качанов, Е. Н. Имянитов, В. Ю. Рощин, Т. В. Шаманская, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 2 (2020); 64-77 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 2 (2020); 64-77 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-2

مصطلحات موضوعية: ген ALK, children, rare tumors, gene ALK, дети, редкие опухоли

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/605/552; Brunn H. Two interesting benign lung tumours of contradictory histopathology: remarks on the necessity for maintaining the chest tumour registry. J Thorac Surg 1939;9:119–31.; Lane J.D., Krohn S., Kolozzi W., Whitehead R.E. Plasma cell granuloma of the lung. Dis Chest 1955;27:216–21. doi:10.1378/chest.27.2.216.; Meis J.M., Enzinger F.M. Infl ammatory fi brosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol 1991;15(12):1146–56. doi:10.1097/00000478-199112000-00005.; Coffi n C.M., Watterson J., Priest J.R., Dehner L.P. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995;19 (8):859–72. doi:10.1097/00000478-199508000-00001.; Alaggio R., Cecchetto G., Bisogno G., Gambini C., Calabrò M.L., Inserra A., Boldrini R., De Salvo G.L., G d’Amore E.S., Dall’igna P. Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group Studies. Cancer 2010;116(1):216–26. doi:10.1002/cncr.24684.; Kube S., Vokuhl C., Dantonello T., Scheer M., Hallmen E., Feuchtgruber S., Escherich G., Niggli F., Kuehnle I., von Kalle T., Bielack S., Klingebiel T., Koscielniak E. Inflammatory myofibroblastic tumors – a retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 2018;65(6):e27012. doi:10.1002/pbc.27012.; Casanova M., Brennan B., Alaggio R., Kelsey A., Orbach D., van Noesel M.M., Corradini N., Minard-Colin V., Zanetti I., Bisogno G., Gallego S., Merks J.H.M., De Salvo G.L., Ferrari A. Inflammatory myofibroblastic tumor: the experience of the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer 2020;127:123–9. doi:10.1016/j.ejca.2019.12.021.; Goldblum J.R., Golpe A.L., Weiss S.W. Benign fibroblastic/myofibroblastic proliferations, including superficial fibromatoses. In: Enzinger and Weiss’s soft tissue tumors. 6th ed. Elsevier Saunders, 2014.; Coffi n C.M., Dehner L.P., Meis-Kindblom J.M. Inflammatory myofi broblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol 1998;15(2):102–10. PMID: 9606802.; Matsubara O., Tan-Liu N.S., Kenney R.M., Mark E.J. Inflammatory pseudotumors of the lung: progression from organizing pneumonia to fi brous histiocytoma or to plasma cell granuloma in 32 cases. Hum Pathol 1988;19(7):807–14. doi:10.1016/s0046-8177(88)80264-8.; Coffi n C.M., Alaggio R. Fibroblastic and myofi broblastic tumors in children and adolescents. Pediatr Dev Pathol 2012;15(1 Suppl):127–80. doi:10.2350/10-12-0944-PB.1.; Lopez-Nunez O., John I., Panasiti R.N., Ranganathan S., Santoro L., Grélaud D., Wu T., Buccoliero A.M., Casanova M., Alaggio R., Surrey L.F. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases. Mod Pathol 2020;33(4):576–90. doi:10.1038/s41379-019-0406-6.; Haimes J.D., Stewart C.J.R., Kudlow B.A., Culver B.P., Meng B., Koay E., Whitehouse A., Cope N., Lee J.C., Ng T., McCluggage W.G., Lee C.H. Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1. Am J Surg Pathol 2017;41(6):773–80. doi:10.1097/PAS.0000000000000801.; Kling E., Kutys R., Virmani R., Miettinen M. Cardiac infl ammatory myofi broblastic tumor: a “benign” neoplasm that may result in syncope, myocardial infarction, and sudden death. Am J Surg Pathol 2007;31(7):1115–22. doi:10.1097/PAS.0b013e31802d68ff .; Liu H.K., Lin Y.C., Yeh M.L., Chen Y.S., Su Y.T., Tsai C.C. Infl ammatory myofi broblastic tumors of the pancreas in children. A case report and literature review. Medicine (Baltimore) 2017;96(2):e5870. doi:10.1097/MD.0000000000005870.; Bumber Z., Jurlina M., Manojlović S., Jakić-Razumović J. Infl ammatory pseudotumor of the trachea. J Pediatr Surg 2001;36(4):631–4. doi:10.1053/jpsu.2001.22306.; Al-Humidi A., Al-Khamiss A. Infl ammatory myofi broblastic tumor arising in the external ear: unexpected location (case report). Int J Health Sci (Qassim) 2015;9(2):201–5. PMID: 26309441.; Lourenço S.V., Boggio P., Simonsen Nico M.M. Infl ammatory myofi broblastic tumor of the tongue: report of an unusual case in a teenage patient. Dermatol Online J 2012;18(5):6. PMID: 22630576.; Качанов Д.Ю., Шаманская Т.В., Сулейманова А.М., Меркулов Н.Н., Феоктистова Е.В., Талыпов С.Р., Рощин В.Ю., Щербаков А.П., Терещенко Г.В., Казакова А.Н., Варфоломеева С.Р. Воспалительная миофибробластическая опухоль брыжейки тонкой кишки, осложнившаяся острой кишечной непроходимостью. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2017;16(1):54–61. doi:10.24287/1726-1708-2017-16-1-54-61.; Souid A.K., Ziemba M.C., Dubansky A.S., Mazur M., Oliphant M., Thomas F.D., Ratner M., Sadowitz P.D. Inflammatory myofibroblastic tumor in children. Cancer 1993;72(6):2042–8. doi:10.1002/10970142(19930915)72:63.0.co;2-i.; Coffin C.M., Fletcher J.A. Inflammatory myofibroblastic tumour. WHO Classification of Tumours of Soft Tissue and Bone. WHO/IARC Classification of Tumours, 4th ed., vol. 5. Fletcher C.D.M., Bridge J.A., Hogendoorn P.C.W., Mertens F. (eds.) International Agency for Research on Cancer. Lyon, 2013. Pр. 83–86.; Hagenstad C.T., Kilpatrick S.E., Pettenati M.J., Savage P.D. Inflammatory myofibroblastic tumor with bone marrow involvement. A case report and review of the literature. Arch Pathol Lab Med 2003;127(7):865–7. doi:10.1043/1543-2165(2003)1272.0.CO;2.; Debelenko L.V., Arthur D.C., Pack S.D., Helman L.J., Schrump D.S., Tsokos M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003;83(9):1255–65. doi:10.1097/01.lab.0000088856.49388.ea.; Fangusaro J., Klopfenstein K., Groner J., Hammond S., Altura R.A. Inflammatory myofi broblastic tumor following hematopoietic stem cell transplantation: report of two pediatric cases. Bone Marrow Transplant 2004;33(1):103–7. doi:10.1038/sj.bmt.1704292.; Cook J.R., Dehner L.P., Collins M.H., Ma Z., Morris S.W., Coffi n C.M., Hill D.A. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 2001;25(11):1364–71. doi:10.1097/00000478-200111000-00003.; Mariño-Enríquez A., Wang W.L., Roy A., Lopez-Terrada D., Lazar A.J., Fletcher C.D., Coffin C.M., Hornick J.L. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of infl ammatory myofi broblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 2011;35(1):135–44. doi:10.1097/PAS.0b013e318200cfd5.; Coffi n C.M., Hornick J.L., Fletcher C.D. Infl ammatory myofi broblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007;31(4):509–20. doi:10.1097/01.pas.0000213393.57322.c7.; Gleason B.C., Hornick J.L. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 2008;61(4):428–37. doi:10.1136/jcp.2007.049387.; Chen C.H., Lin R.L., Liu H.C., Chen C.H., Hung T.T., Huang W.C. Inflammatory myofibroblastic tumor mimicking anterior mediastinal malignancy. Ann Thorac Surg 2008;86(4):1362–4. doi:10.1016/j.athoracsur.2008.03.031.; Hornick J.L., Sholl L.M., Dal Cin P., Childress M.A., Lovly C.M. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofi broblastic tumors. Mod Pathol 2015;28(5):732–9. doi:10.1038/modpathol.2014.165.; Gatalica Z., Xiu J., Swensen J., Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32(1):147–53. doi:10.1038/s41379-018-0118-3.; Cottrell T.R., Duong A.T., Gocke C.D., Xu H., Ogurtsova A., Taube J.M., Belchis D.A. PD-L1 expression in inflammatory myofibroblastic tumors. Mod Pathol 2018;31(7):1155–63. doi:10.1038/s41379-018-0034-6.; Zen Y., Kitagawa S., Minato H., Kurumaya H., Katayanagi K., Masuda S., Niwa H., Fujimura M., Nakanuma Y. IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Hum Pathol 2005;36(7):710–7. doi:10.1016/j.humpath.2005.05.011.; Griffi n C.A., Hawkins A.L., Dvorak C., Henkle C., Ellingham T., Perlman E.J. Recurrent involvement of 2p23 in infl ammatory myofi broblastic tumors. Cancer Res 1999;59(12):2776–80. PMID: 10383129.; Sokai A., Enaka M., Sokai R., Mori S., Gunji M., Fujino M., Ito M. Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene. Jpn J Clin Oncol 2014;44(1):93–6. doi:10.1093/jjco/hyt173.; Antonescu C.R., Suurmeijer A.J., Zhang L., Sung Y.S., Jungbluth A.A., Travis W.D., Al-Ahmadie H., Fletcher C.D., Alaggio R. Molecular characterization of infl ammatory myofi broblastic tumors with frequent ALK and ROS1 fusions and rare novel RET gene rearrangement. Am J Surg Pathol 2015;39(7):957–67. doi:10.1097/PAS.0000000000000404.; Coffi n C.M., Patel A., Perkins S., Elenitoba-Johnson K.S., Perlman E., Griffi n C.A. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14(6):569–76. doi:10.1038/modpathol.3880352.; Lawrence B., Perez-Atayde A., Hibbard M.K., Rubin B.P., Dal Cin P., Pinkus J.L., Pinkus G.S., Xiao S., Yi E.S., Fletcher C.D., Fletcher J.A. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157(2):377–84. doi:10.1016/S0002-9440(10)64550-6.; Lovly C.M., Gupta A., Lipson D., Otto G., Brennan T., Chung C.T., Borinstein S.C., Ross J.S., Stephens P.J., Miller V.A., Coffi n C.M. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 2014;4(8):889–95. doi:10.1158/2159-8290.CD-14-0377.; Chang J.C., Zhang L., Drilon A.E., Chi P., Alaggio R., Borsu L., Benayed R., Travis W.D., Ladanyi M., Antonescu C.R. Thoracic infl ammatory myofi broblastic tumors beyond ALK gene rearrangements. J Thorac Oncol 2019;14(5):825–34. doi:10.1016/j.jtho.2018.12.003.; Baldi G.G., Gronchi A., Vincenzi B., Martino De Pas T., Pantaleo M.A., D’Ambrosio L., Grignani G., Casanova M., Ferrari A., Simeone N., Provenzano S., Dei Tos A.P., Sbaraglia M., Collini P., Dagrada G., Morosi C., Casali P.G., Stacchiotti S. Activity of chemotherapy in infl ammatory myofi broblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR). J Clin Oncol 2019;37(15 suppl). doi:10.1200/JCO.2019.37.15_suppl.e22545.; Applebaum H., Kieran M.W., Cripe T.P., Coffi n C.M., Collins M.H., Kaipainen A., Laforme A., Shamberger R.C. The rationale for nonsteroidal anti-infl ammatory drug therapy for infl ammatory myofi broblastic tumors: a Children’s Oncology Group Study. J Pediatr Surg 2005;40(6):999–1003;discussion 1003. doi:10.1016/j.jpedsurg.2005.03.016.; Maire J.P., Eimer S., San Galli F., Franco-Vidal V., Galland-Girodet S., Huchet A., Darrouzet V. Infl ammatory myofi broblastic tumour of the skull base. Case Rep Otolaryngol 2013;2013:103646. doi:10.1155/2013/103646.; Sasagawa Y., Akai T., Itou S., Iizuka H. Multiple intraosseous infl ammatory myofi broblastic tumors presenting with an aggressive clinical course: case report. Neurosurgery 2011;69(4):E1010–5;discussion E1015-6. doi:10.1227/NEU.0b013e318223b651.; Butrynski J.E., D’Adamo D.R., Hornick J.L., Dal Cin P., Antonescu C.R., Jhanwar S.C., Ladanyi M., Capelletti M., Rodig S.J., Ramaiya N., Kwak E.L., Clark J.W., Wilner K.D., Christensen J.G., Jänne P.A., Maki R.G., Demetri G.D., Shapiro G.I. Crizotinib in ALK-rearranged infl ammatory myofi broblastic tumor. N Engl J Med 2010;363(18):1727–33. doi:10.1056/NEJMoa1007056.; Mossé Y.P., Lim M.S., Voss S.D., Wilner K., Ruff ner K., Laliberte J., Rolland D., Balis F.M., Maris J.M., Weigel B.J., Ingle A.M., Ahern C., Adamson P.C., Blaney S.M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 2013;14(6):472–80. doi:10.1016/S1470-2045(13)70095-0.; Mossé Y.P., Voss S.D., Lim M.S., Rolland D., Minard C.G., Fox E., Adamson P., Wilner K., Blaney S.M., Weigel B.J. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and infl ammatory myofi broblastic tumor: a Children’s Oncology Group Study. J Clin Oncol 2017;35(28):3215–21. doi:10.1200/JCO.2017.73.4830.; Schöff ski P., Sufl iarsky J., Gelderblom H., Blay J.Y., Strauss S.J., Stacchiotti S., Rutkowski P., Lindner L.H., Leahy M.G., Italiano A., Isambert N., Debiec-Rychter M., Sciot R., Van Cann T., Marréaud S., Nzokirantevye A., Collette S., Wozniak A. Crizotinib in patients with advanced, inoperable infl ammatory myofi broblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): A multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med 2018;6(6):431–41. doi:10.1016/S2213-2600(18)30116-4.; Brivio E., Zwaan C.M. ALK inhibition in two emblematic cases of pediatric infl ammatory myofi broblastic tumor: Effi cacy and side eff ects. Pediatr Blood Cancer 2019;66(5):e27645. doi:10.1002/pbc.27645.; Ambati S.R., Slotkin E.K., Chow-Maneval E., Basu E.M. Entrectinib in two pediatric patients with infl ammatory myofi broblastic tumors harboring ROS1 or ALK gene fusions. JCO Precis Oncol 2018;2018. doi:/10.1200/PO.18.00095.; Parker B.M., Parker J.V., Lymperopoulos A., Konda V. A case report: pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic infl ammatory myofi broblastic sarcoma. J Oncol Pharm Pract 2019;25(5):1226–30. doi:10.1177/1078155218781944.; Alassiri A.H., Ali R.H., Shen Y., Lum A., Strahlendorf C., Deyell R., Rassekh R., Sorensen P.H., Laskin J., Marra M., Yip S., Lee C.H., Ng T.L. ETV6-NTRK3 is expressed in a subset of ALK-negative infl ammatory myofi broblastic tumors. Am J Surg Pathol 2016;40(8):1051–61. doi:10.1097/PAS.0000000000000677.; Schram A.M., Chang M.T., Jonsson P., Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol 2017;14(12):735–48. doi:10.1038/nrclinonc.2017.127.; Shaw A.T., Friboulet L., Leshchiner I., Gainor J.F., Bergqvist S., Brooun A., Burke B.J., Deng Y.L., Liu W., Dardaei L., Frias R.L., Schultz K.R., Logan J., James L.P., Smeal T., Timofeevski S., Katayama R., Iafrate A.J., Le L., McTigue M., Getz G., Johnson T.W., Engelman J.A. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016;374(1):54–61. doi:10.1056/NEJMoa1508887.; Cerfolio R.J., Allen M.S., Nascimento A.G., Deschamps C., Trastek V.F., Miller D.L., Pairolero P.C. Infl ammatory pseudotumors of the lung. Ann Thorac Surg 1999;67(4):933–6. doi:10.1016/s0003-4975(99)00155-1.; Chun Y.S., Wang L., Nascimento A.G., Moir C.R., Rodeberg D.A. Pediatric infl ammatory myofi broblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr Blood Cancer 2005;45(6):796–801. doi:10.1002/pbc.20294.; Morotti R.A., Legman M.D., Kerkar N., Pawel B.R., Sanger W.G., Coffi n C.M. Pediatric infl ammatory myofi broblastic tumor with late metastasis to the lung: case report and review of the literature. Pediatr Dev Pathol 2005;8(2):224–9. doi:10.1007/s10024-004-8088-5.; Hussong J.W., Brown M., Perkins S.L., Dehner L.P., Coffi n C.M. Comparison of DNA ploidy, histologic, and immunohistochemical fi ndings with clinical outcome in infl ammatory myofi broblastic tumors. Mod Pathol 1999;12(3):279–86. PMID: 10102613.; Yamamoto H., Yamaguchi H., Aishima S., Oda Y., Kohashi K., Oshiro Y., Tsuneyoshi M. Infl ammatory myofi broblastic tumor versus IgG4-related sclerosing disease and infl ammatory pseudotumor: a comparative clinicopathologic study. Am J Surg Pathol 2009;33(9):1330–40. doi:10.1097/pas.0b013e3181a5a207.; Biselli R., Ferlini C., Fattorossi A., Boldrini R., Bosman C. Infl ammatory myofi broblastic tumor (infl ammatory pseudotumor): DNA fl ow cytometric analysis of nine pediatric cases. Cancer 1996;77(4):778–84. doi:10.1002/(sici)1097-0142(19960215)77:43.0.co;2-x.; Donner L.R., Trompler R.A., White R.R. Progression of infl ammatory myofi broblastic tumor (infl ammatory pseudotumor) of soft tissue into sarcoma after several recurrences. Hum Pathol 1996;27(10):1095–8. doi:10.1016/s0046-8177(96)90291-9.; https://journal.nodgo.org/jour/article/view/605

الاتاحة: https://journal.nodgo.org/jour/article/view/605
https://doi.org/10.21682/2311-1267-2020-7-2-64-77

المؤلفون: G. B. Sagoyan, M. Sh. Shingarova, T. V. Shamanskaya, D. G. Akhaladze, N. N. Merkulov, R. A. Moiseenko, N. G. Uskova, V. Yu. Roshchin, E. S. Ternovaya, A. N. Novikov, I. V. Fisyun, D. Yu. Kachanov, S. R. Varfolomeeva, Г. Б. Сагоян, М. Ш. Шингарова, Т. В. Шаманская, Д. Г. Ахаладзе, Н. Н. Меркулов, Р. А. Моисеенко, Н. Г. Ускова, В. Ю. Рощин, Е. С. Терновая, А. Н. Новиков, И. В. Фисюн, Д. Ю. Качанов, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 105-112 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 105-112 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4

مصطلحات موضوعية: паранеопластический синдром, children, secretory diarrhea, vasoactive intestinal peptide, paraneoplastic syndrome, дети, секреторная диарея, вазоактивный интестинальный пептид

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/450/432; Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202–11. doi:10.1056/NEJMra0804577.; Goodman M.S., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L. Jr, Bunin G.R., eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975– 1995. National Cancer Institute, SEER Program. Bethesda, MD, 1999. Pp. 65–72.; Spix C., Pastore G., Sankila R., Stiller C.A., Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978– 1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi:10.1016/j.ejca.2006.05.008.; Геворков А.Р. Паранеопластические синдромы. В кн.: Онкология: национальное руководство. Под ред. В.И. Чиссова, М.И. Давыдова. М.: ГЭОТАР-Медиа, 2008. С. 547–570. [Gevorkov A.R. Paraneoplastic syndromes. In: Oncology: National guidelines. Edited by V.I. Chissov, M.I. Davydov. M.: GEOTAR-Media, 2008. Pp. 547–570. (In Russ.)].; Качанов Д.Ю., Шаманская Т.В., Малевич О.Б., Варфоломеева С.Р. Синдром опсоклонус-миоклонус и нейробластома (обзор литературы). Российский журнал детской гематологии и онкологии 2014;1(1):62–9. doi:10.17650/2311-1267-2014-0-1-62-69. [Kachanov D.Yu., Shamanskaya T.V., Malevich O.B., Varfolomeeva S.R. Opsoclonusmyoclonus syndrome and neuroblastoma (a review of literature). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2014;1(1):62–9. doi:10.17650/2311-1267-2014-0-1-62-69. (In Russ.)].; Qureshi S.S., Bhagat M., Anam J., Vora T. Aggressive cervical neuroblastoma with a rare paraneoplastic syndrome: A therapeutic dilemma. J Indian Assoc Pediatr Surg 2016;21(4):181–3. doi:10.4103/0971-9261.186548.; Bourdeaut F., de Carli E., Timsit S., Coze C., Chastagner P., Sarnacki S., Delattre O., Peuchmaur M., Rubie H., Michon J.; Neuroblastoma Committee of the Société Française des Cancers et Leucémies de l’Enfant et de l’Adolescent. VIP Hypersecretion as Primary or Secondary Syndrome in Neuroblastoma: A Retrospective Study by the Société Française des Cancers de l’Enfant (SFCE). Pediatr Blood Cancer 2009;52(5):585–90. doi:10.1002/pbc.21912.; Farthing M., Salam M., Lindberg G., Dite P., Khalif I., Salazar-Lindo E., Ramakrishna B.S., Goh K., Thomson A., Khan A.G., Krabshuis J., LeMair A. Acute diarrhea in adults and children: a global perspective. World Gastroenterology Organisation Global Guidelines, 2012. [Electronic resource]: http://www. worldgastroenterology.org/UserFiles/fi le/guidelines/acute-diarrheaenglish-2012.pdf (appeal date 20.09.2018).; Verner J.V., Morrison A.B. Islet cell tumor and a syndrome of refractory watery diarrhoea and hypokalemia. Am J Med 1958;25:374–80. PMID: 13571250.; Green M., Cooke R.E., Lattanzi W. Occurrence of chronic diarrhea in three patients with ganglioneuromas. Pediatrics 1959;23(5):951–5. PMID: 13645132.; Balemba O.B., Grondahl M.L., Mbassa G.K., Semuguruka W.D., HaySmith A., Skadhauge E., Dantzer V. The organization of the enteric nervous system in the submucous and mucous layers of the small intestine of the pig studied by VIP and neurofi lament protein immunohistochemistry. J Anat 1998;192(Pt 2):257–67. doi:10.1046/j.1469-7580.1998.19220257.x.; Pincus D.W., DiCicco-Bloom E.M., Black I.B. Vasoactive intestinal peptide regulates mitosis, diff erentiation and survival of cultured sympathetic neuroblasts. Nature 1990;343(6258):564–7. doi:10.1038/343564a0.; Tiedemann K., Long R.G., Pritchard J., Bloom S.R. Plasma vasoactive intestinal polypeptide and other regulatory peptides in children with neurogenic tumours. Eur J Pediatr 1981;137(2):147–50. PMID: 7308225.; Tiedemann K., Pritchard J., Long R., Bloom S.R. Intractable diarrhea in a patient with vasoactive intestinal peptide-secreting neuroblastoma. Attempted control by somatostatin. Eur J Pediatr 1981;137(2):217–9. PMID: 6118274.; Adam N., Lim S.S., Ananda V., Chan S.P. VIPoma syndrome: challenges in management. Singapore Med J 2010;51(7):e129–32. PMID: 20730389.; Kabalan P., Giff ord A.J., Ziegler D.S. Unresectable VIP-secreting neuroblastoma: Effi cacy of debulking and steroids for symptom control. Pediatr Blood Cancer 2018;65(12):e27358. doi:10.1002/pbc.27358.; https://journal.nodgo.org/jour/article/view/450

الاتاحة: https://journal.nodgo.org/jour/article/view/450
https://doi.org/10.17650/2311-1267-2018-5-4-105-112

المؤلفون: D. V. Shevtsov, T. V. Shamanskaya, D. Yu. Kachanov, N. S. Grachev, K. I. Kirgizov, G. M. Muftakhova, V. Yu. Roshchin, G. V. Tereshchenko, Yu. V. Olshanskaya, Yu. N. Likar, S. R. Varfolomeeva, Д. В. Шевцов, Т. В. Шаманская, Д. Ю. Качанов, Н. С. Грачёв, К. И. Киргизов, Г. М. Муфтахова, В. Ю. Рощин, Г. В. Терещенко, Ю. В. Ольшанская, Ю. Н. Ликарь, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 21-30 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 21-30 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4

مصطلحات موضوعية: жизнеугрожающие состояния, neuroblastoma, oncology, neck, age, localization, risk group, polychemotherapy, survival, life threatening conditions, нейробластома, онкология, область шеи, возраст, локализация, группа риска, химиотерапия, выживаемость

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/438/420; Ward E., DeSantis C., Robbins A., Betsy K., Ahmedin J. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64(2):83–103. doi:10.3322/caac.21219.; Bénard J.L., Raguénez G., Kauff mann A., Valent A., Ripoche H., Joulin V., Job B., Danglot G., Cantais S., Robert T., Terrier-Lacombe M.J., Chassevent A., Koscielny S., Fischer M., Berthold F., Lipinski M., Tursz T., Dessen P., Lazar V., Valteau-Couanet D. MYCN-non-amplifi ed metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2008;2(3):261–71. doi:10.1016/j.molonc.2008.07.002.; Ahmed A.A., Zhang L., Reddivalla N., Hetherington M. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol 2017;34(3):165–85. doi:10.1080/08880018.2017.1330375.; Alvi S., Karadaghy O., Manalang M., Weatherly R. Clinical manifestations of neuroblastoma with head and neck involvement in children. Int J Pediatr Otorhinolaryngol 2017;97:157–62. doi:10.1016/j.ijporl.2017.04.013.; Качанов Д.Ю., Шаманская Т.В., Муфтахова Г.М., Варфоломеева С.Р. Нейробластома 4S стадии (обзор литературы). Вопросы гематологии/онкологии и иммунологии в педиатрии 2014;13(2):63–8. [Kachanov D.Yu., Shamanskaya T.V., Muftakhova G.M., Varfolomeeva S.R. Stage 4S neuroblastoma (literature review). Voprosy gematologii/ onkologii i immunopatologii v pediatrii = Pediatric Hematology/ Oncology and Immunopathology 2014;13(2):63–8. (In Russ.)].; Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The International Neuroblastoma Pathology Classifi cation (the Shimada System). Cancer 1999;86(2):364–72. PMID: 10421273.; Cheung N.-K.V., Cohn S.L. (eds.). Neuroblastoma. Springer, 2005. 300 р. doi:10.1007/b137762.; Choi D.K., Schmidt M.L. Chemotherapy in Children with Head and Neck Cancers: Perspectives and Review of Current Therapies. Oral Maxillofac Surg Clin North Am 2016;28(1):127–38. doi:10.1016/j.coms.2015.08.004.; Csanády M., Vass G., Bartyik K., Majoros V., Rovó L. Multidisciplinary management of cervical neuroblastoma in infants. Int J Pediatr Otorhinolaryngol 2014;78(12):2103–6. doi:10.1016/j.ijporl.2014.09.015.; Haddad M., Triglia J.M., Helardot P., Couanet D., Gauthier F., Neuenschwander S., Bourlière B., Bergeron C., Munzer C., Rubie H., Guys J.M.; French Society of Pediatric Oncology. Localized cervical neuroblastoma: prevention of surgical complications. Int J Pediatr Otorhinolaryngol 2003;67(12):1361–7. PMID: 14643482.; Frank D.K., Ramaswamy G., Tavin E., Moscatello A.L. Poorly diff erentiated pediatric head and neck neuroblastoma: a diagnostic dilemma. Int J Pediatr Otorhinolaryngol 1995;33(2):103–11. PMID: 7499043.; Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., Mattay K.K., Hogarty M.; COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60(6):985–93. doi:10.1002/pbc.24433.; Qureshi S.S., Kembhavi S., Ramadwar M., Chinnaswamy G., Laskar S., Talole S., Desai S., Khanna N., Vora T., Kurkure P. Outcome and morbidity of surgical resection of primary cervical and cervicothoracic neuroblastoma in children: a comparative analysis. Pediatr Surg Int 2014;30(3):267–73. doi:10.1007/s00383-013-3431-4.; Vo K.T., Matthay K.K., Neuhaus J., London W.B., Hero., Ambros P.F., Nakagawara A., Miniati D., Wheeler K., Pearson A.D., Cohn S.L., DuBois S.G. Clinical, biologic, and prognostic diff erences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol 2014;32(28):3169–76. doi: 0.1200/JCO.2014.56.1621.; Cardesa-Salzmann T.M., Mora-Graupera J., Claret G., Agut T. Congenital cervical neuroblastoma. Pediatr Blood Cancer 2004;43(7):785–7. doi:10.1002/pbc.20190.; Brown R.E., Harave S. Diagnostic imaging of benign and malignant neck masses in children-a pictorial review. Quant Imaging Med Surg 2016;6(5):591–604. doi:10.21037/qims.2016.10.10.; Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., Kaneko M., London W.B., Matthay K.K., Nuchtern J.G., von Schweinitz D., Simon T., Cohn S.L., Pearson A.D. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298–303. doi:10.1200/JCO.2008.16.6876.; NB-2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma/Berthold F. (principal investigator) https://www. kinderkrebsinfo.de/sites/kinderkrebsinfo/content/e1676/e9032/e1758/ e7671/download7673/NB_2004_1.00_komprimiert__ger.pdf.; Moukheiber A.K., Nicollas R., Roman S., Coze C., Triglia J.M. Primary pediatric neuroblastic tumors of the neck. Int J Pediatr Otorhinolaryngol 2001;60(2):155–61.; Okazaki T., Ohshita M., Furukawa M., Ikeda K., Ozaki Y., Lane G.J., Yamataka A. Retropharyngeal neuroblastoma in a neonate: case report and literature review. Pediatr Surg Int 2007;23(10):1023–6. doi:10.1007/s00383-007-1990-y.; Abramson S.J., Berdon W.E., Ruzal-Shapiro C., Stolar C., Garvin J. Cervical neuroblastoma in eleven infants – a tumor with favorable prognosis. Clinical and radiologic (US, CT, MRI) fi ndings. Pediatr Radiol 1993;23(4):253–7. PMID: 8414748. Rubie H., Hartmann O., Michon J., Frappaz D., Coze C., Chastagner P., Baranzelli M.C., Plantaz D, Avet-Loiseau H., Benard J., Delattre O., Favrot M., Peyroulet M.C., Thyss A., Perel Y., Bergeron C., CourbonCollet B., Vannier J.P., Lemerle J., Sommelet D. N-Myc gene amplifi cation is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d’Oncologie Pédiatrique. J Clin Oncol 1997;15(3):1171–82. doi:10.1200/JCO.1997.15.3.1171.; https://journal.nodgo.org/jour/article/view/438

الاتاحة: https://journal.nodgo.org/jour/article/view/438
https://doi.org/10.17650/2311-1267-2018-5-4-21-30

المؤلفون: A. M. Suleymanova, S. S. Ozerov, V. Yu. Roshchin, N. S. Grachev, N. A. Bolshakov, A. E. Druy, G. V. Tereshchenko, D. M. Konovalov, G. B. Sagoyan, T. V. Shamanskaya, D. Yu. Kachanov, S. R. Varfolomeeva, А. М. Сулейманова, С. С. Озеров, В. Ю. Рощин, Н. С. Грачёв, Н. А. Большаков, А. Е. Друй, Г. В. Терещенко, Д. М. Коновалов, Г. Б. Сагоян, Т. В. Шаманская, Д. Ю. Качанов, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 6, № 3 (2019); 44-53 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 6, № 3 (2019); 44-53 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2019-6-3

مصطلحات موضوعية: доброкачественные опухоли, rare tumor, children, melanotic progonoma, benign tumor, редкие опухоли, дети, меланотическая прогонома

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/525/491; Barnes L., Eveson J.W., Reichart P., Sidransky D. World Health Organization classification of tumors. Pathology and genetics, malignant soft tissue tumors, vol. 149. Lyon: IARC Press, 2005.; Kruse-Lösler B., Gaertner C., Bürger H., Seper L., Joos U., Kleinheinz J. Melanotic neuroectodermal tumor of infancy: systematic review of the literature and presentation of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102 (2):204–16. PMID: 16876064. doi:10.1016/j.tripleo.2005.08.010.; Stowens D., Lin T.H. Melanotic progonoma of the brain. Hum Pathol 1974;5(1):105–13. doi:10.1016/s0046-8177(74)80104-8.; Elli M., Aydin O., Pinarli F.G., Dagdemir A., Dabak N., Selcuk M.B., Acar S. Melanotic neuroectodermal tumor of infancy of the femur. Pediatr Hematol Oncol 2006;23(7):579–86. PMID: 16928653. doi:10.1080/08880010600812561.; Choi I.S., Kook H., Han D.K., Baek H.J., Jung S.T., Lee J.H., Park J.G., Hwang T.J. Melanotic neuroectodermal tumor of infancy in the femur: a case report and review of the literature. J Pediatr Hematol Oncol 2007;29(12):854–7. doi:10.1097/MPH.0b013e31815815ae.; Batsakis J.G. Pathology consultation: melanotic neuroectodermal tumor of infancy. Ann Otol Rhinol Laryngol 1987;96:128–9. PMID: 3028235. doi:10.1177/000348948709600132.; Nicosia G., Spennato P., Aliberti F., Cascone D., Quaglietta L., Errico M.E., Muto M., Ionna F., Cinalli G. Giant melanotic neuroectodermal tumor of infancy (melanotic progonoma) of the head and neck: report of a malignant case. J Neurosurg Pediatr 2017;19(5):538–45. PMID: 28291424. doi:10.3171/2016.11.PEDS16509.; Kumari T.P., Venugopal M., Mathews A., Kusumakumary P. Effectiveness of chemotherapy in melanotic neuroectodermal tumor of infancy. Pediatr Hematol Oncol 2005;22(3):199–206. PMID: 16020102 doi:10.1080/08880010590921450.; Hered R.W., Smithwick W. 4th, Sandler E., Goldstein J.D. Orbital melanotic neuroectodermal tumor of infancy successfully treated with chemotherapy and subtotal excision. J AAPOS 2007;11(5):504–5. PMID: 17532239. doi:10.1016/j.jaapos.2007.03.010.; Cohen B.H., Handler M.S., De Vivo D.C., Garvin J.H. Jr, Hays A.P., Carmel P. Central nervous system melanotic neuroectodermal tumor of infancy: value of chemotherapy in management. Neurology 1988;38(1):163–4. PMID: 2827053. doi:10.1212/wnl.38.1.163-a.; Krombecher E. Zur Histogenese und Morphologie der Adamantinome und sonstiger Kiefergeschwulste. Beitr Pathol Anat Allg Pathol. 1918;64:165–97.; Lurie H.I. Congenital melanocarcinoma, melanotic adamantinoma, retinal anlage tumor, progonoma, and pigmented epulis of infancy. Cancer 1961;14(5):1090–1108. doi:10.1002/1097-0142(196109/10)14:5; Borello E.D., Gorlin R.J. Melanotic neuroectodermal tumor of infancy – a neoplasm of neural crest origin. Report of a case associated with high urinary excretion of vanilmandelic acid. Cancer 1966;19(2):196–206. doi:10.1002/1097-0142(196602)19:23.0.co;2-6.; Derache A.F., Rocourt N., Delattre C., Vinchon M., Orbach D., Leblond P. Les tumeurs neuroectodermiques melanotiques infantiles: etat actuel des connaissances. Bull Cancer 2014;101:е626–36. doi:10.1684/bdc.2014.1985.; Sapru B.L., Jeyaraj P., Mukherjee B. Melanotic neuroectodermal tumor of infancy. Med J Armed Forces India 2002;58(3):253–6. doi:10.1016/S0377-1237(02)80142-3.; Haque S., McCarville M.B., Sebire N., McHugh K. Melanotic neuroectodermal tumor of infancy: CT and MR findings. Ped Radiol 2012;42:e699–705. doi:10.1007/s00247-011-2339-1.; Suzuki C., Maeda M., Matsushima N., Takamura M., Matsubara T., Taki W., Takeda K. Melanotic neuroectodermal tumor of infancy in the skull: CT and MRI features. J Neuroradiol 2007;34(3):212–3. PMID: 17582497. doi:10.1016/j.neurad.2007.04.006.; Cates J.M.M., Coffi n C.M. Neurogenic tumors of soft tissue. prospective of pediatric pathology. Pediatr Dev Pathol 2012;15(1suppl):62–107. PMID: 22420725. doi:10.2350/11-03-1003-PB.1.; Higashi K., Ogawa T., Onuma M., Usubuchi H., Imai Y., Takata I., Hidaka H., Watanabe M., Sasahara Y., Koyama S., Kure S., Katori Y. Clinicopathological features of melanotic neuroectodermal tumor of infancy: Report of two cases. Auris Nasus Larynx 2016;43(4):451–4. doi:10.1016/j.anl.2015.10.010.; Dehner L.P., Sibley R.K., Sauk J.J. Jr, Vickers R.A., Nesbit M.E., Leonard A.S., Waite D.E., Neeley J.E., Ophoven J. Malignant melanotic neuroectodermal tumor of infancy: a clinical, pathological, ultrastructural and tissue culture study. Cancer 1979;43(4):1389–410. PMID: 221089. doi:10.1002/1097-0142(197904)43:43.0.co;2-v.; Kapandia S.B., Frisman D.M., Hitchcock C.L., Ellis G.L., Popek E.J. Melanotic neuroectodermal tumor of infancy: clinicopathological, immunohistochemical, and flow cytometric study. Am J Surg Pathol 1993;17(6):566–73. PMID: 8392815. doi:10.1097/00000478-199306000-00004.; Barrett A.W., Morgan M., Ramsay A.D., Farthing P.M., Newman L., Speight P.M. A clinicopathologic and immunohistochemical analysis of melanotic neuroectodermal tumor of infancy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93(6):688–98. PMID: 12142876.; Soles B.S., Wilson A., Lucas D.R., Heider A. Melanotic neuroectodermal tumor of infancy. Arch Pathol Lab Med 2018;142(11):1358–63. doi:10.5858/arpa.2018-0241-RA.; de Souza D.F., Sendyk D.I., Seo J., da Fonseca E.V., Naclério-Homem M. da G., Deboni M.C. Melanotic neuroectodermal tumor of infancy in the maxilla. Case Rep Dent 2013;2013:726815. doi:10.1155/2013/726815.; Moreau A., Galmiche L., Minard-Colin V., Rachwalski M., Belhous K., Orbach D., Joly A., Picard A., Kadlub N. Melanotic neuroectodermal tumor of infancy (MNTI) of the head and neck: a French multicenter study. J Craniomaxillofac Surg 2018;46(2):201–6. doi:10.1016/j.jcms.2017.12.001.; Gomes C.C., Diniz M.G., de Menezes G.H., Castro W.H., Gomez R.S. BRAFV600E Mutation in Melanotic Neuroectodermal Tumor of Infancy: Toward Personalized Medicine? Pediatrics 2015;136(1):e267–9. doi:10.1542/peds.2014-3331.; Neven J., Hulsbergen-van der Kaa C., Groot-Loonen J., de Wilde P.C., Merkx M.A. Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106(4):493–6. doi:10.1016/j.tripleo.2008.02.001.; Barnes D.J., Hookway E., Athanasou N., Kashima T., Oppermann U., Hughes S., Swan D., Lueerssen D., Anson J., Hassan A.B. A germline mutation of CDKN2A and a novel RPLP1-C19MC fusion detected in a rare melanotic neuroectodermal tumor of infancy: a case report. BMC Cancer 2016;16:629. doi:10.1186/s12885-016-2669-3.; Retna Kumari N., Sreedharan S., Balachandran D. Melanotic neuroectodermal tumor of infancy: a case report. J Indian Soc Pedod Prev Dent 2007;25(3):e148–51. PMID: 17951934.; Woessmann W., Neugebauer M., Gossen R., Blü tters-Sawatzki R., Reiter A. Successful chemotherapy for melanotic neuroectodermal tumor of infancy in a baby. Med Pediatr Oncol 2003;40:е198–204. PMID: 12518354. doi:10.1002/mpo.10135.; Atkinson G.O. Jr, Davis P.C., Patrick L.E., Winn K.J., Ball T.I., Wyly J.B. Melanotic neuroectodermal tumor of infancy: MR fi ndings and a review of the literature. Pediatr Radiol 1989;20:е20–2. PMID: 2557574. doi:10.1007/bf02010627.; PDQ Pediatric Treatment Editorial Board: Neuroblastoma treatment (PDQ®): health professional version. In: PDQ cancer information summaries [Internet]. Bethesda (MD): National Cancer Institute (US) [cited 2016 Jul 19]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK65747/;2002.; Rachidi S., Sood A.J., Patel K.G. Melanotic neuroectodermal tumor of infancy: a systematic review. J Oral Maxillofac Surg 2015;73(10):1946–56. doi:10.1016/j.joms.2015.03.061.; https://journal.nodgo.org/jour/article/view/525

الاتاحة: https://journal.nodgo.org/jour/article/view/525
https://doi.org/10.21682/2311-1267-2019-6-3-44-53

المؤلفون: G. B. Sagoyan, Yu. M. Mareeva, V. Yu. Roshchin, N. S. Grachev, D. M. Konovalov, A. E. Druy, V. P. Bondarenko, M. A. Alekseev, G. S. Ovsyannikova, D. V. Litvinov, N. V. Zhukov, Г. Б. Сагоян, Ю. М. Мареева, В. Ю. Рощин, Н. С. Грачёв, Д. М. Коновалов, А. Е. Друй, В. П. Бондаренко, М. А. Алексеев, Г. С. Овсянникова, Д. В. Литвинов, Н. В. Жуков

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 86-93 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 86-93 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4

مصطلحات موضوعية: кобиметиниб, ameloblastic fibrosarcoma, undifferentiated round cell sarcoma, transformation, BRAF V600E mutation, vemurafenib, cobimetinib, амелобластная фибросаркома, недифференцированная круглоклеточная саркома, трансформация, мутация BRAF V600E, вемурафениб

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/444/426; Adekeye E.O., Lavery K.M. Recurrent ameloblastoma of the maxillofacial region. Clinical features and treatment. J Maxillofac Surg 1986;14:153–7. PMID: 3459793.; Hayashi N., Iwata J., Masaoka N., Ueno H., Ohtsuki Y., Moriki T. Ameloblastoma of the mandible metastasizing to the orbit with malignant transformation. A histopathological and immunohistochemical study. Virchows Arch 1997;430(6):501–7. PMID: 9230916.; Kessler H.P. Intraosseous ameloblastoma. Oral Maxillofac Surg Clin North Am 2004;16(3):309–22. doi:10.1016/j.coms.2004.03.001.; Sweeney R.T., Clary A.C., Myers B.R., Biscocho J., Neahring L., Kwei K.A., Qu K., Gong X., Ng T., Jones C.D., Varma S., Odegaard J.I., Sugiyama T., Koyota S., Rubin B.P., Troxell M.L., Pelham R.J., Zehnder J.L., Beachy P.A., Pollack J.R., West R.B. Identifi cation of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 2014;46:722–5. doi:10.1038/ng.2986.; Shaikhi K., Neiders M., Chen F., Aguirre A. Morphological variants of ameloblastoma and their mimickers. NAJ Med Sci 2012;5(1):20–8. doi:10.7156/v5i1p020.; Rais R., El-Mofty S.K. Malignant Transformation of a Desmoplastic Ameloblastoma to Squamous Cell Carcinoma: A Case Report. Head and Neck Pathol 2018. [Epub ahead of print]. doi:10.1007/s12105-018-0946-y.; Nobusawa A., Sano T., Yokoo S., Oyama T. Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118(5):e146–50. doi:10.1016/j.oooo.2014.03.02112.; Brown N.A., Rolland D.C., McHugh J.B. Weigelin H.C., Zhao L., Lim M.S., Elenitoba-Johnson K.S., Betz B.L. Activating FGFR2- RASBRAF mutations in ameloblastoma. Clin Cancer Res 2014;20:5517–26. doi:10.1158/1078-0432.CCR-14-1069.; Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399(3):313–7. doi:10.1016/j.bbrc.2010.07.092.; Tang X., Guo X., Sun L.Y., Ai Y., Yang X., Sun J.J., Wu J.R., Gao J. BRAF-V600E mutation and its clinical signifi cance in children with Langerhans cell histiocytosis. Zhongguo Dang Dai Er Ke Za Zhi 2018;20(4):290–4. PMID: 29658453.; Pappo A.S. Pediatric melanoma: the whole (genome) story. Am Soc Clin Oncol Educ Book 2014:e432–5. doi:10.14694/EdBook_ AM.2014.34.e432.; Wegert J., Vokuhl C., Collord G., Del Castillo Velasco-Herrera M., Farndon S. J., Guzzo C., Jorgensen M., Anderson J., Slater O., Duncan C., Bausenwein S., Streitenberger H., Ziegler B., Furtwängler R., Graf N., Stratton M.R., Campbell P.J., Jones D.T., Koelsche C., Pfi ster S.M., Mifsud W., Sebire N., Sparber-Sauer M., Koscielniak E., Rosenwald A., Gessler M., Behjati S. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 2018;9(1):2378. doi:10.1038/s41467-018-04650-6.; Dahiya S., Emnett R.J., Haydon D.H., Leonard J.R., Phillips J.J., Perry A., Gutmann D.H. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 2014;16(2):318–9. doi:10.1093/neuonc/not146.; Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346–56. doi:10.1097/PAT.0b013e328360b61d.; Kurppa K.J., Caton J., Morgan P.R., Ristimäki A., Ruhin B., Kellokoski J., Elenius K., Heikinheimo K. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014;232:492–8. doi:10.1002/path.4317.; Fregnani E.R., Perez D.E., Paes de Almeida O., Fonseca F.P., Soares F.A., Castro-Junior G., Alves F. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology 2017;70(3):473–84. doi:10.1111/his.13095.; Menzies A.M., Long G.V. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 2014;15(9):e371–e381. doi:10.1016/S1470-2045(14)70072-5.; Holderfi eld M., Deuker M.M., McCormick F., McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;7:455–67. doi:10.1038/nrc3760.; Ascierto P.A., Schadendorf D., Berking C., Agarwala S.S., van Herpen C.M., Queirolo P., Blank C.U., Hauschild A., Beck J.T., St-Pierre A., Niazi F., Wandel S., Peters M., Zubel A., Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14(3):249–56. doi:10.1016/S1470-2045(13)70024-X.; Tan S., Pollack J.R., Kaplan M.J., Colevas A.D., West R.B. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122(1):e5–7. doi:10.1016/j.oooo.2015.12.016.; Faden D.L., Algazi A. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 2016;109(1). pii: djw190. doi:10.1093/jnci/djw190.; Heikinheimo К., Kurppa K.J., Elenius K. Novel Targets for the Treatment of Ameloblastoma. J Dent Res 2015;94(2):237–40. doi:10.1177/0022034514560373.; https://journal.nodgo.org/jour/article/view/444

الاتاحة: https://journal.nodgo.org/jour/article/view/444
https://doi.org/10.17650/2311-1267-2018-5-4-86-93

المؤلفون: M. M. Burgol, D. Yu. Kachanov, V. Yu. Roshchin, A. M. Suleymanova, N. N. Merkulov, A. N. Kazakova, A. P. Shcherbakov, G. V. Tereshchenko, T. V. Shamanskaya, S. R. Varfolomeeva, М. М. Бургол, Д. Ю. Качанов, В. Ю. Рощин, А. М. Сулейманова, Н. Н. Меркулов, А. Н. Казакова, А. П. Щербаков, Г. В. Терещенко, Т. В. Шаманская, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 1 (2018); 87-94 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 1 (2018); 87-94 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-1

مصطلحات موضوعية: клинический случай, children, case report, дети

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/364/362; Enzinger F.M. Angiomatoid malignant fibrous histiocytoma: a distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer 1979;44(6):2147– 57. PMID: 228836.; Antonescu C.R., Rossi S. Angiomatoid fibrous histiocytoma. In: Fletcher C.D.M., Bridge J.A., Hogendoorn P.C.W., Mertens F., eds. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC, 2013. Pp. 204–205.; Costa M.J., Weiss S.W. Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome. Am J Surg Pathol 1990;14(12):1126–32. PMID: 2174650.; Fanburg-Smith J.C., Dal Cin P. Angiomatoid fibrous histiocytoma. In: Fletcher C.D.M., Unni K.K., Mertens F. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, 2002. P. 194–195.; Saito K., Kobayashi E., Yoshida A. et al. Angiomatoid fibrous histiocytoma: a series of seven cases including genetically confirmed aggressive cases and a literature review. BMC Musculoskelet Disord 2017;18(1):31. doi:10.1186/s12891-017-1390-y.; Antonescu C.R., Dal Cin P., Nafa K. et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer 2007;46(12):1051–60. doi:10.1002/gcc.20491.; Thway K., Fisher C. Angiomatoid fibrous histiocytoma: the current status of pathology and genetics. Arch Pathol Lab Med 2015;139(5):674– 82. doi:10.5858/arpa.2014-0234-RA.; Bauer A., Jackson B., Marner E., Gilbertson-Dahdal D. Angiomatoid fibrous histiocytoma: a case report and review of the literature. J Radiol Case Rep 2012;6(11):8–15. doi:10.3941/jrcr.v6i11.932.; Martinez S.J., Moreno C.C., Vinson E.N., Dodd L.G., Brigman B.E. Angiomatoid fibrous histiocytoma: novel MR imaging findings. Skeletal Radiol 2016;45(5):661–70. doi:10.1007/s00256-016-2344-4.; Chen G., Folpe A.L., Colby T.V. et al. Angiomatoid fibrous histiocytoma: unusual sites and unusual morphology. Mod Pathol 2011;24(12):1560– 70. doi:10.1038/modpathol.2011.126.; Akiyama M., Yamaoka M., Mikami-Terao Y. et al. Paraneoplastic Syndrome of Angiomatoid Fibrous Histiocytoma May Be Caused by EWSR1-CREB1 Fusion-induced Excessive Interleukin-6 Production. J Pediatr Hematol Oncol 2015;37(7):554–9. doi:10.1097/MPH.0000000000000390.; Weiss S.W., Goldblum J.R. Fibrohistiocytic tumors of intermediate malignancy. In: Weiss S.W., Goldblum J.R., eds. Enzinger and Weiss’s soft tissue tumors. 5th ed. Elsevier, 2008. Pp. 390–394.; Maher O.M., Prieto V.G., Stewart J., Herzog C.E. Characterization of metastatic angiomatoid fibrous histiocytoma. J Pediatr Hematol Oncol 2015;37(4):e268–71. doi:10.1097/MPH.0000000000000313.; Wegmann W., Heitz P.U. Angiomatoid malignant fibrous histiocytoma: evidence for the histiocytic origin of tumor cells. Virchows Arch A Pathol Anat Histopathol 1985;406(1):59–66. PMID: 2986350.; Tanas M.R., Rubin B.P., Montgomery E.A. et al. Utility of FISH in the diagnosis of angiomatoid fibrous histiocytoma: a series of 18 cases. Mod Pathol 2010;23(1):93–7. doi:10.1038/modpathol.2009.138.; Yikilmaz A., Ngan B.Y., Navarro O.M. Imaging of childhood angiomatoid fibrous histiocytoma with pathological correlation. Pediatr Radiol 2015;45(12):1796–802. doi:10.1007/s00247-015-3404-y.; Ulaner G.A., Healey J.H., Athanasian E.A. Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma. Clin Orthop Relat Res 2017;475(9):2274–9. doi:10.1007/s11999-017-5388-4.; Daw N.C., Billups C.A., Pappo A.S. et al. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients: the St. Jude Children’s Research Hospital experience. Cancer 2003;97(11):2839–47. doi:10.1002/cncr.11384.; Ogden S., Harave S., McPartland J. et al. Angiomatoid fibrous histiocytoma: A case of local recurrence and metastases to loco-regional lymph nodes that responded to chemotherapy. Pediatr Blood Cancer 2017;64(6). doi:10.1002/pbc.26376.; Bernini J.C., Fort D.W., Pritchard M., Rogers B.B., Winick N.J. Adjuvant chemotherapy for treatment of unresectable and metastatic angiomatoid malignant fibrous histiocytoma. Cancer 1994;74(3):962–4. PMID: 8039125.; Costa M.A., Silva I., Carvalhido L. et al. Angiomatoid fibrous histiocytoma of the arm treated by radiotherapy for local recurrence – case report. Med Pediatr Oncol 1997;28(5):373–6. PMID: 9121405.; Brisse H., Orbach D., Klijanienko J., Freneaux P., Neuenschwander S. Imaging and diagnostic strategy of soft tissue tumors in children. Eur Radiol 2006;16(5):1147–64. doi:10.1007/s00330-005-0066-4.; https://journal.nodgo.org/jour/article/view/364

الاتاحة: https://journal.nodgo.org/jour/article/view/364
https://doi.org/10.17650/2311-1267-2018-5-1-87-94

المؤلفون: T. V. Sergeeva, D. Yu. Kachanov, Т. V. Shamanskaya, A. P. Shcherbakov, G. V. Tereshchenko, N. N. Merkulov, S. R. Talypov, V. Yu. Roshchin, D. M. Konovalov, S. R. Varfolomeeva, Т. В. Сергеева, Д. Ю. Качанов, Т. В. Шаманская, А. П. Щербаков, Г. В. Терещенко, Н. Н. Меркулов, С. Р. Талыпов, В. Ю. Рощин, Д. М. Коновалов, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 4, № 3 (2017); 97-101 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 4, № 3 (2017); 97-101 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2017-4-3

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/324/323; Messinger Y.H., Stewart D.R., Priest J.R. et al. Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer 2015;121(2):276–85. doi:10.1002/ cncr.29032.; Dehner L.P., Watterson J., Priest J.R. Pleuropulmonary blastoma. A unique intrathoracic-pulmonary neoplasm of childhood. Perspectives in Pediatric Pathology 1995;18:214–26.; Priest J.R., Watterson J., Strong L. et al. Pleuropulmonary blastoma: a marker for familial disease. J Pediatr 1996;128(2):220–4. PMID: 8636815.; Calabria R., Srikanth M.S., Chamberlin K., Bloch J., Atkinson J.B. Management of pulmonary blastoma in children. Am Surg 1993;59(3):192–6. PMID: 8476159.; Wright J.R. Pleuropulmonary blastoma: A case report documenting transition from type I (cystic) to type III (solid). Cancer 2000;88(12):2853–8. PMID: 10870072.; Priest J.R., Hill D.A., Williams G.M. et al. Type I pleuropulmonary blastoma: a report from the International Pleuropulmonary Blastoma Registry. J Clin Oncol 2006;24(27):4492–8. doi:10.1200/ JCO.2005.05.3595.; Priest J.R., Williams G.M., Hill D.A., Dehner L.P., Jaffé A. Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol 2009;44(1):14–30. doi:10.1002/ppul.20917.; Hill D.A., Ivanovich J., Priest J.R. et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009;325(5943):965. doi:10.1126/science.1174334.; Feinberg A., Hall N.J., Williams G.M. et al. Can congenital pulmonary airway malformation be distinguished from Type I pleuropulmonary blastoma based on clinical and radiological features? J Pediatr Surg 2016;51(1):33–7. doi:10.1016/j.jpedsurg.2015.10.019.; https://journal.nodgo.org/jour/article/view/324

الاتاحة: https://journal.nodgo.org/jour/article/view/324
https://doi.org/10.17650/2311-1267-2017-4-3-97-101